Overview

The Optimal Sequential Therapy After Long Term Denosumab Treatment

Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study intends to investigate whether Alendronate and Zoledronate can prevent bone mineral density loss after long-term treatment with Denosumab.
Phase:
Phase 4
Details
Lead Sponsor:
National Taiwan University Hospital
Treatments:
Alendronate
Zoledronic Acid